School of Medicine, Tibet University, Lhasa, Tibet, China.
School of Life Science and Engineering, Southwest Jiaotong University, Chengdu, Sichuan, China.
BMC Cardiovasc Disord. 2024 Feb 21;24(1):119. doi: 10.1186/s12872-024-03742-0.
This study evaluates the effectiveness of a combined regimen involving injectable hydrogels for the treatment of experimental myocardial infarction.
Myocardial infarction is an acute illness that negatively affects quality of life and increases mortality rates. Experimental models of myocardial infarction can aid in disease research by allowing for the development of therapies that effectively manage disease progression and promote tissue repair.
Experimental animal models of myocardial infarction were established using the ligation method on the anterior descending branch of the left coronary artery (LAD).
The efficacy of intracardiac injection of hydrogels, combined with cells, drugs, cytokines, extracellular vesicles, or nucleic acid therapies, was evaluated to assess the functional and morphological improvements in the post-infarction heart achieved through the combined hydrogel regimen.
A literature review was conducted using PubMed, Web of Science, Scopus, and Cochrane databases. A total of 83 papers, including studies on 1332 experimental animals (rats, mice, rabbits, sheep, and pigs), were included in the meta-analysis based on the inclusion and exclusion criteria. The overall effect size observed in the group receiving combined hydrogel therapy, compared to the group receiving hydrogel treatment alone, resulted in an ejection fraction (EF) improvement of 8.87% [95% confidence interval (CI): 7.53, 10.21] and a fractional shortening (FS) improvement of 6.31% [95% CI: 5.94, 6.67] in rat models, while in mice models, the improvements were 16.45% [95% CI: 11.29, 21.61] for EF and 5.68% [95% CI: 5.15, 6.22] for FS. The most significant improvements in EF (rats: MD = 9.63% [95% CI: 4.02, 15.23]; mice: MD = 23.93% [95% CI: 17.52, 30.84]) and FS (rats: MD = 8.55% [95% CI: 2.54, 14.56]; mice: MD = 5.68% [95% CI: 5.15, 6.22]) were observed when extracellular vesicle therapy was used. Although there have been significant results in large animal experiments, the number of studies conducted in this area is limited.
The present study demonstrates that combining hydrogel with other therapies effectively improves heart function and morphology. Further preclinical research using large animal models is necessary for additional study and validation.
本研究评估了包含注射水凝胶的联合方案治疗实验性心肌梗死的效果。
心肌梗死是一种急性疾病，会降低生活质量并增加死亡率。心肌梗死的实验模型可以通过开发有效管理疾病进展和促进组织修复的治疗方法来帮助疾病研究。
使用结扎法在左冠状动脉前降支（LAD）上建立实验性心肌梗死动物模型。
评估了心内注射水凝胶联合细胞、药物、细胞因子、细胞外囊泡或核酸治疗的疗效，以评估通过联合水凝胶方案实现的梗死后心脏的功能和形态改善。
使用 PubMed、Web of Science、Scopus 和 Cochrane 数据库进行文献回顾。根据纳入和排除标准，共有 83 篇论文，包括 1332 只实验动物（大鼠、小鼠、兔子、绵羊和猪）的研究，被纳入荟萃分析。与单独接受水凝胶治疗的组相比，接受联合水凝胶治疗的组观察到射血分数（EF）改善 8.87%[95%置信区间（CI）：7.53，10.21]和短轴缩短率（FS）改善 6.31%[95%CI：5.94，6.67]大鼠模型，而在小鼠模型中，EF 的改善分别为 16.45%[95%CI：11.29，21.61]和 FS 的改善为 5.68%[95%CI：5.15，6.22]。EF 的最大改善（大鼠：MD=9.63%[95%CI：4.02，15.23]；小鼠：MD=23.93%[95%CI：17.52，30.84]）和 FS（大鼠：MD=8.55%[95%CI：2.54，14.56]；小鼠：MD=5.68%[95%CI：5.15，6.22]）是当使用细胞外囊泡治疗时观察到的。尽管在大动物实验中已经取得了显著的结果，但该领域的研究数量有限。
本研究表明，联合水凝胶与其他疗法可有效改善心脏功能和形态。需要使用大动物模型进行进一步的临床前研究以进行进一步的研究和验证。
